HPV vaccination in the vaccination clinic of Shaanxi Provincial Center for Disease Control and Prevention
10.3969/j.issn.1006-2483.2022.01.029
- VernacularTitle:陕西省疾控中心预防接种门诊HPV疫苗接种情况分析
- Author:
Yanhui JIAO
1
,
2
,
3
;
Xueqin XIA
4
,
5
;
Weijun HU
4
,
5
Author Information
1. School of Nursing, Xi'
2. an Medical College , Xi'
3. an 710021 , China
4. Shaanxi Provincial Center for Disease Control and Prevention , Xi'
5. an 710054, China
- Publication Type:Journal Article
- Keywords:
Human papillomavirus;
cervical cancer;
vaccine
- From:
Journal of Public Health and Preventive Medicine
2022;33(1):132-135
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the HPV vaccination situation in the vaccination clinic of Shaanxi Provincial Center for Disease Control and Prevention, and to guide the rational use of the vaccine. Methods The vaccination information and the information on HPV vaccine inoculated subjects in the clinic of Shaanxi Provincial Center for Disease Control and Prevention from 2018 to 2019 were analyzed. Results A total of 5 714 HPV vaccination subjects were analyzed, among which the largest proportion (48.97%) was in the 20-26.5 years old group, and the smallest proportion (1.12%) was in the 9-15 years old group. The 9-valent HPV vaccination accounted for 98.72% of the 20-26.5-year-old group. There were statistically significant differences in the distribution of vaccination populations between the bivalent and quadrivalent HPV vaccines (P＜0.01，χ2=252.85), and between the bivalent and 9-valent HPV vaccines (P＜0.01，χ2=258.15). The vaccination rate of the bivalent HPV vaccine was 88.25% (894/1 013), and the vaccination rate of the quadrivalent HPV vaccine was 94.43% (1 915/2 028). The difference was statistically significant (Z=-2.02, P=0.043). Conclusion Vaccination subjects tend to choose high-valent HPV vaccines, and the proportion of HPV vaccination in the younger age group is seriously insufficient. Both bivalent and quadrivalent HPV vaccines have relatively high overall vaccination rates. The next step should be to strengthen the vaccination publicity for younger age groups.
